Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives

By Crystal Lubbe

December 12, 2024

The article from the Africa CDC website, titled “Egypt’s Hepatitis Programme Becomes a Model for African Countries,” highlights Egypt’s successful hepatitis C elimination program, which serves as a benchmark for other African countries. By implementing the “100 Million Healthier Lives” campaign, Egypt has achieved Gold-tier certification for its progress toward eliminating hepatitis C, as recognised by the World Health Organization (WHO). This remarkable achievement showcases how effective public health initiatives can lead to significant health improvements across the continent.

Egypt’s Hepatitis C Elimination Program

Egypt Hepatitis C Program has benefited its citizens and set a powerful example for other African nations. Notably, the country has made significant strides in training and capacity building.

Training and Capacity Building

The Africa CDC, in collaboration with Egypt’s Ministry of Health and Population, has implemented training programs for experts from various African Union member states. These programs are designed to equip participants with the necessary skills to launch “screen-and-treat” programs for hepatitis C. To date, 26 members have been trained, with an additional cohort of 31 participants from multiple African countries completing their training in November 2024.

Regional Collaboration and Support

Moreover, Egypt plays a pivotal role by providing technical support, screening software, and free treatment for one million people in 14 African nations. This collaborative effort aligns with WHO screening and treatment guidelines.

Best Practices and Challenges

The training includes lectures, field trips, and discussions on best practices and challenges in hepatitis elimination. Participants visit hospitals, healthcare settings, and pharmaceutical companies to understand Egypt’s comprehensive strategy.

Africa CDC’s Role

The Africa CDC is actively supporting African nations by funding seroprevalence surveys, providing necessary kits and drugs, and training health workers. For example, Madagascar is currently undergoing a capacity and readiness assessment for viral hepatitis elimination, as part of the support provided by the Africa CDC.

South-South Cooperation

The initiative promotes South-South cooperation, encouraging shared learning and collaboration to improve public health outcomes continent-wide. This approach is a cornerstone of Egypt’s hepatitis C elimination successes and its potential replicability in other African countries.

Action Plans and Future Initiatives

Country representatives create action plans to apply training and identify needed support from Africa CDC and Egypt. For example, Cameroon is poised to launch a Triple elimination strategy, guided by the training and support it has received.

Conclusion

Egypt Hepatitis C Program stands as a model for other African countries. Notably thanks to its comprehensive approach, innovative financing, and political commitment. The program’s achievements signal a promising pathway toward the global goal of eliminating viral hepatitis by 2030. With continued regional collaboration and strong action plans, the impact of Egypt’s efforts will undoubtedly resonate across the continent.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.